ViroGates publishes prospectus for its initial public offering in Copenhagen.

ViroGates intends to strengthen its capital structure to intensify the continued commercial roll-out of its products and strengthen its product development, clinical documentation and global patent coverage.

ViroGates therefore today publishes the prospectus for an offering of new shares and subsequent admission to trading and listing of the shares on Nasdaq First North in Denmark.

The offering will provide ViroGates with gross proceeds of DKK 60-75 million of which commitments of DKK 53.7 million have been obtained from Scandinavian cornerstone investors, including the Danish Growth Fund.

The proceeds from the offering are primarily expected to be used for:
• 60-70% for commercial execution, i.e. building a sales organization in the European markets, as well as establishing commercial partnerships in selected markets
• 10-20% to secure necessary product development
• 5-10% to generate additional clinical documentation
• 5-10% to secure the global coverage of the most recently filed patent on the use of suPARnostic® in emergency department

The objective is for the business to be cash flow positive by the end of 2020 and at this point have 40 hospitals as paying customers.

More information to be found in ViroGates´ announcement published on June 4 here; ViroGates_Prospektmeddelelse_012018_ENG.pdf

 

Read more in the press reviews here (in Danish):

Børsen; Medicoselskab med Coloplast-milliardærer i ryggen vil på børsen

Finans.dk; Medicoselskab vil på børsen

MedWatch; ViroGates går på børsen i København

Berlingske Business.dk; Coloplast-milliardærer bag ny børsnotering